vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and GRID DYNAMICS HOLDINGS, INC. (GDYN). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $104.1M, roughly 1.3× GRID DYNAMICS HOLDINGS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -1.4%, a 36.9% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 3.7%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 12.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Escape Dynamics, Inc. was a Colorado-based technology company that operated 2010–2015 focused on bringing to market single-stage-to-orbit reusable electromagnetically powered spaceplanes.
ADMA vs GDYN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $104.1M |
| Net Profit | $49.4M | $-1.5M |
| Gross Margin | 63.8% | 34.8% |
| Operating Margin | 45.1% | 61.7% |
| Net Margin | 35.5% | -1.4% |
| Revenue YoY | 18.4% | 3.7% |
| Net Profit YoY | -55.9% | -150.6% |
| EPS (diluted) | $0.20 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.1M | ||
| Q4 25 | $139.2M | $106.2M | ||
| Q3 25 | $134.2M | $104.2M | ||
| Q2 25 | $122.0M | $101.1M | ||
| Q1 25 | $114.8M | $100.4M | ||
| Q4 24 | $117.5M | $100.3M | ||
| Q3 24 | $119.8M | $87.4M | ||
| Q2 24 | $107.2M | $83.0M |
| Q1 26 | — | $-1.5M | ||
| Q4 25 | $49.4M | $306.0K | ||
| Q3 25 | $36.4M | $1.2M | ||
| Q2 25 | $34.2M | $5.3M | ||
| Q1 25 | $26.9M | $2.9M | ||
| Q4 24 | $111.9M | $4.5M | ||
| Q3 24 | $35.9M | $4.3M | ||
| Q2 24 | $32.1M | $-817.0K |
| Q1 26 | — | 34.8% | ||
| Q4 25 | 63.8% | 34.0% | ||
| Q3 25 | 56.3% | 33.3% | ||
| Q2 25 | 55.1% | 34.1% | ||
| Q1 25 | 53.2% | 36.8% | ||
| Q4 24 | 53.9% | 36.9% | ||
| Q3 24 | 49.8% | 37.4% | ||
| Q2 24 | 53.6% | 35.6% |
| Q1 26 | — | 61.7% | ||
| Q4 25 | 45.1% | 0.5% | ||
| Q3 25 | 38.0% | -0.2% | ||
| Q2 25 | 35.1% | -0.1% | ||
| Q1 25 | 30.4% | -2.0% | ||
| Q4 24 | 32.6% | 1.3% | ||
| Q3 24 | 33.1% | 2.4% | ||
| Q2 24 | 36.6% | 0.0% |
| Q1 26 | — | -1.4% | ||
| Q4 25 | 35.5% | 0.3% | ||
| Q3 25 | 27.1% | 1.1% | ||
| Q2 25 | 28.1% | 5.2% | ||
| Q1 25 | 23.4% | 2.9% | ||
| Q4 24 | 95.2% | 4.5% | ||
| Q3 24 | 30.0% | 4.9% | ||
| Q2 24 | 29.9% | -1.0% |
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $0.20 | $0.01 | ||
| Q3 25 | $0.15 | $0.01 | ||
| Q2 25 | $0.14 | $0.06 | ||
| Q1 25 | $0.11 | $0.03 | ||
| Q4 24 | $0.45 | $0.06 | ||
| Q3 24 | $0.15 | $0.05 | ||
| Q2 24 | $0.13 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $327.5M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $530.1M |
| Total Assets | $624.2M | $605.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $327.5M | ||
| Q4 25 | $87.6M | $342.1M | ||
| Q3 25 | $61.4M | $338.6M | ||
| Q2 25 | $90.3M | $336.8M | ||
| Q1 25 | $71.6M | $325.5M | ||
| Q4 24 | $103.1M | $334.7M | ||
| Q3 24 | $86.7M | $231.3M | ||
| Q2 24 | $88.2M | $256.0M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $530.1M | ||
| Q4 25 | $477.3M | $542.1M | ||
| Q3 25 | $431.2M | $537.7M | ||
| Q2 25 | $398.3M | $532.2M | ||
| Q1 25 | $373.4M | $517.4M | ||
| Q4 24 | $349.0M | $517.8M | ||
| Q3 24 | $231.9M | $400.2M | ||
| Q2 24 | $188.3M | $388.4M |
| Q1 26 | — | $605.0M | ||
| Q4 25 | $624.2M | $612.9M | ||
| Q3 25 | $568.7M | $613.2M | ||
| Q2 25 | $558.4M | $608.9M | ||
| Q1 25 | $510.6M | $590.9M | ||
| Q4 24 | $488.7M | $592.2M | ||
| Q3 24 | $390.6M | $477.3M | ||
| Q2 24 | $376.4M | $443.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $9.9M | ||
| Q3 25 | $13.3M | $7.0M | ||
| Q2 25 | $21.1M | $14.4M | ||
| Q1 25 | $-19.7M | $9.4M | ||
| Q4 24 | $50.2M | $7.1M | ||
| Q3 24 | $25.0M | $9.2M | ||
| Q2 24 | $45.6M | $10.7M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $6.1M | ||
| Q3 25 | $-1.1M | $2.9M | ||
| Q2 25 | $18.7M | $10.2M | ||
| Q1 25 | $-24.4M | $6.0M | ||
| Q4 24 | $47.5M | $4.4M | ||
| Q3 24 | $24.0M | $5.9M | ||
| Q2 24 | $43.6M | $8.0M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 5.7% | ||
| Q3 25 | -0.8% | 2.8% | ||
| Q2 25 | 15.3% | 10.1% | ||
| Q1 25 | -21.2% | 6.0% | ||
| Q4 24 | 40.4% | 4.4% | ||
| Q3 24 | 20.0% | 6.8% | ||
| Q2 24 | 40.7% | 9.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 3.6% | ||
| Q3 25 | 10.7% | 3.9% | ||
| Q2 25 | 2.0% | 4.1% | ||
| Q1 25 | 4.1% | 3.3% | ||
| Q4 24 | 2.3% | 2.6% | ||
| Q3 24 | 0.9% | 3.7% | ||
| Q2 24 | 1.9% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 32.34× | ||
| Q3 25 | 0.36× | 5.92× | ||
| Q2 25 | 0.62× | 2.73× | ||
| Q1 25 | -0.73× | 3.21× | ||
| Q4 24 | 0.45× | 1.56× | ||
| Q3 24 | 0.70× | 2.15× | ||
| Q2 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
GDYN
Segment breakdown not available.
